{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T19:16:33Z","timestamp":1780427793918,"version":"3.54.1"},"reference-count":23,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2015,4,7]],"date-time":"2015-04-07T00:00:00Z","timestamp":1428364800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Clin Appl Thromb Hemost"],"published-print":{"date-parts":[[2015,10]]},"abstract":"<jats:p>Venous thromboembolism (VTE) is a common complication in patients with cancer. Previous randomized studies have demonstrated that the rates of recurrent VTE are lower in patients treated with low-molecular-weight heparin compared to warfarin. We performed a retrospective analysis of 236 patients with cancer managed by a dedicated oncology anticoagulation management service to compare \u201creal-world\u201d rates of recurrent VTE and bleeding in patients treated with warfarin versus parenteral anticoagulants. Initial anticoagulant regimen included a parenteral agent with transition to warfarin in 132 (55.9%) patients, enoxaparin in 53 (22.5%), dalteparin in 37 (15.7%), and fondaparinux in 14 (5.9%). Taking into account the competing risk of death, cumulative incidence of VTE recurrence at 6 months was 4.0% with warfarin, 10.3% with enoxaparin, 3.0% with dalteparin, and 7.7% with fondaparinux ( P = .004). Bleeding complications occurred in 10.6% of patients on warfarin, 17.0% on enoxaparin, 27.0% on dalteparin, and 14.3% on fondaparinux ( P = .089). In a dedicated anticoagulation clinic, specific for patients with cancer, warfarin may be an acceptable treatment for first thrombotic events in patients with cancer.<\/jats:p>","DOI":"10.1177\/1076029615579099","type":"journal-article","created":{"date-parts":[[2015,4,8]],"date-time":"2015-04-08T00:20:28Z","timestamp":1428452428000},"page":"632-638","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":11,"title":["Recurrence of Venous Thromboembolism in Patients With Cancer Treated With Warfarin"],"prefix":"10.1177","volume":"21","author":[{"given":"Ariela L.","family":"Marshall","sequence":"first","affiliation":[{"name":"Department of Hematology and Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Campigotto","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Neuberg","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betty","family":"Rowe","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA"},{"name":"Hematology Division, Brigham and Women\u2019s Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean M.","family":"Connors","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA"},{"name":"Hematology Division, Brigham and Women\u2019s Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2015,4,7]]},"reference":[{"key":"bibr1-1076029615579099","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-499087"},{"key":"bibr2-1076029615579099","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.6.715"},{"key":"bibr3-1076029615579099","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.6.809"},{"key":"bibr4-1076029615579099","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1613051"},{"key":"bibr5-1076029615579099","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27772"},{"key":"bibr6-1076029615579099","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001275"},{"key":"bibr7-1076029615579099","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.8197"},{"key":"bibr8-1076029615579099","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.4.458"},{"key":"bibr9-1076029615579099","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012213432504"},{"key":"bibr10-1076029615579099","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-01-0108"},{"key":"bibr11-1076029615579099","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa025313"},{"key":"bibr12-1076029615579099","doi-asserted-by":"publisher","DOI":"10.1177\/1078155212464892"},{"key":"bibr13-1076029615579099","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.162.15.1729"},{"key":"bibr14-1076029615579099","doi-asserted-by":"publisher","DOI":"10.1177\/1076029606293692"},{"key":"bibr15-1076029615579099","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2006.02.022"},{"key":"bibr16-1076029615579099","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2012.04766.x"},{"key":"bibr17-1076029615579099","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2011.07.005"},{"key":"bibr18-1076029615579099","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06679.x"},{"key":"bibr19-1076029615579099","doi-asserted-by":"publisher","DOI":"10.1177\/1078155210397775"},{"issue":"3","key":"bibr20-1076029615579099","first-page":"131","volume":"5","author":"Pangilinan JM","year":"2007","journal-title":"J Support Oncol"},{"key":"bibr21-1076029615579099","unstructured":"National Comprehensive Cancer Center Clinical Guidelines in Oncology. Cancer Associated Venous Thromboembolic Disease. Version 2.2014. NCCN.org. Web site. http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/vte.pdf. Accessed January 23, 2014."},{"issue":"2","key":"bibr22-1076029615579099","doi-asserted-by":"crossref","first-page":"19S","DOI":"10.1378\/chest.11-2301","volume":"141","author":"Kearon C","year":"2012","journal-title":"Chest"},{"key":"bibr23-1076029615579099","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.1118"}],"container-title":["Clinical and Applied Thrombosis\/Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1076029615579099","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1076029615579099","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1076029615579099","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:05:44Z","timestamp":1777385144000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1076029615579099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,7]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["10.1177\/1076029615579099"],"URL":"https:\/\/doi.org\/10.1177\/1076029615579099","relation":{},"ISSN":["1076-0296","1938-2723"],"issn-type":[{"value":"1076-0296","type":"print"},{"value":"1938-2723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,7]]}}}